<DOC>
	<DOCNO>NCT00785421</DOCNO>
	<brief_summary>To evaluate safety efficacy chemotherapy without enoxaparin . This study power decrease DVT/ VTE event rate 10 % 3 % enoxaparin experimental arm . N=540pts , dropout-rate 15 % , power 80 % , two side , significant level 5 %</brief_summary>
	<brief_title>Chemotherapy With Without Enoxaparin Pancreatic Cancer</brief_title>
	<detailed_description>Approximately 20 % patient ( pt ) diagnose pancreatic adenocarcinoma ( PA ) develop venous thromboembolism , may contribute dismal prognosis PA. A small phase II trial suggest improved survival addition low molecular weight heparin ( LMWH ) chemotherapy . We conduct small pilot study indicate addition enoxaparin chemotherapy GFFC chemotherapy safe feasible pt advance PA . Furthermore , result several phase III study suggest pt good performance status may benefit intensive chemotherapy regimen ( Riess et al ; Heinemann et al ; ASCO 2005 ) . Based consideration start multicenter phase III study CONKO 004 . 540 patient recruit study . Primary stratification take place accord Karnofsky performance status kidney function . Patients KPS &gt; 80 % normal kidney function receive GFFC +/- LMWH ( gemcitabine 1 g/m2 ( 30 min ) , cisplatin 30 mg/m2 ( 90 min ) , 5-fluorouracil 750 mg/m2 ( 24 h ) , folinic acid 200 mg/m2 ( 30 min ) , d1 , 8 ; q3w +/- Enoxaparin 1mg/kg daily s.c. ) . Pts KPS &lt; 80 % increase creatinin plasma level ( &gt; 1.3 mg/dl ) receive current standard therapy ( gemcitabine 1 g/m2 ( 30 min ) , d1 , 8 , 15 ; q4w ) +/- LMWM +/- Enoxaparin 1mg/kg daily s.c. After 12 week initial chemotherapy patient progress received standard therapy ( gemcitabine mono ) +/- Enoxaparin 40mg/d s.c .</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Leucovorin</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<mesh_term>Folic Acid</mesh_term>
	<criteria>histological cytological pancreatic carcinoma , stage IV A , b preceding radio chemotherapy primarius reference lesion Karnofsky performance status ≥ 60 % measurable tumor lesion spiral CT MRT old 14 day deep venous thrombosis within last 2 year patient compliance geographical proximity residence , make adequate follow possible sufficient bone marrow reserve : leukocyte ≥ 3.5 × 109 /l , thrombocyte ≥ 100 × 109 /l sign informed consent minimum age 18 year women/men must provide sufficient pregnancy prevention preexist indication anticoagulation reason bleed last 2 week increase bleed risk ( e.g . serious coagulate disturbance , active stomach intestine ulzera , operational interference last 2 week ) body weight &lt; 45 kg and/or &gt; 100 kg pregnancy insufficient prevent method study process serious illness , incompatible study participation hypersensitivity study drug patient serious kidney malfunction ( Creatininclearance &lt; 30 ml/min )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>heparin</keyword>
	<keyword>LMWH</keyword>
	<keyword>pancreatic cancer</keyword>
</DOC>